|
gptkbp:instanceOf
|
antidiabetic drug
thiazolidinedione
|
|
gptkbp:approvalYear
|
1999
|
|
gptkbp:approvedBy
|
gptkb:Japan
|
|
gptkbp:ATCCode
|
A10BG03
|
|
gptkbp:bioavailability
|
83%
|
|
gptkbp:brand
|
gptkb:Actos
|
|
gptkbp:CASNumber
|
111025-46-8
|
|
gptkbp:category
|
hypoglycemic agent
antihyperglycemic agent
|
|
gptkbp:chemicalFormula
|
C19H20N2O3S
|
|
gptkbp:contraindication
|
heart failure
active bladder cancer
|
|
gptkbp:developer
|
gptkb:Takeda
|
|
gptkbp:drugClass
|
thiazolidinedione
|
|
gptkbp:eliminationHalfLife
|
3-7 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
pioglitazone
|
|
gptkbp:interactsWith
|
gptkb:insulin
gptkb:rifampin
gptkb:gemfibrozil
oral contraceptives
|
|
gptkbp:KEGGID
|
D08445
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
PPAR-gamma agonist
|
|
gptkbp:MedlinePlusID
|
a699016
|
|
gptkbp:metabolism
|
liver
active metabolites
|
|
gptkbp:molecularWeight
|
356.44 g/mol
|
|
gptkbp:pregnancyCategory
|
gptkb:B3
C (US)
|
|
gptkbp:prescriptionStatus
|
Rx-only
|
|
gptkbp:proteinBinding
|
>99%
|
|
gptkbp:PubChem_CID
|
4829
CHEMBL726
DB01132
|
|
gptkbp:riskFactor
|
gptkb:macular_edema
liver dysfunction
fluid retention
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
edema
weight gain
bone fracture risk
heart failure risk
bladder cancer risk
|
|
gptkbp:synonym
|
AD-4833
pioglitazone hydrochloride
|
|
gptkbp:UNII
|
TGQ8TVL5F9
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes
|
|
gptkbp:bfsParent
|
gptkb:CYP2C8
|
|
gptkbp:bfsLayer
|
6
|